UNIRAD UK Sample collection
Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease (UNIRAD).
Existing samples:
- Malignant tumor of breast (disorder)
Contact Information
- Email:
- unirad-icrctsu@icr.ac.uk
- Address:
-
15 Cotswold Road
Sutton
Surrey
SM2 5NG
England
Annual Statistics
| Year | Access Requests Received | Access Requests Approved | ||||
|---|---|---|---|---|---|---|
| Internal | External | Commercial | Internal | External | Commercial | |
| 2015 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2016 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2019 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2025 | N/A | N/A | N/A | N/A | N/A | N/A |